5-MeO-NiPT, also known as 5-methoxy-N-isopropyltryptamine, is a psychedelic drug of the tryptamine family related to 5-MeO-DMT.
The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT<sub>2A</sub> receptor.
5-MeO-NiPT was encountered as a novel designer and recreational drug by 2014.
5-MeO-NiPT was not included nor mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved).
5-MeO-NiPT is a full agonist or near-full agonist of the serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> receptors. It is inactive as a serotonin releasing agent and is very weak as a serotonin reuptake inhibitor.
Unlike most other N-monoalkylated tryptamines, 5-MeO-NiPT produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents, albeit relatively weakly. It also produces hypolocomotion and hypothermia in rodents. In combination with the serotonin 5-HT<sub>1A</sub> receptor antagonist WAY-100635 however, 5-MeO-NiPT instead produces hyperlocomotion.
5-MeO-NiPT is an active metabolite of 5-MeO-MiPT and 5-MeO-DiPT.
Analogues of 5-MeO-NiPT include N-isopropyltryptamine (NiPT), 5-MeO-NMT, 5-MeO-NET, 5-MeO-DiPT, and 5-MeO-MiPT, among others.
5-MeO-NiPT is not a controlled substance in Canada.
5-MeO-NiPT is a controlled substance in Sweden.
5-MeO-NiPT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.